Richard Furman

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She competed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College. Dr. Mulvey has also completed a Master's Degree in Clinical Investigation and Translational Research at the Weill Cornell School of Graduate Sciences.

Dr. Mulvey is a member of the Weill Cornell Lymphoma Program where she specializes in treating patients with lymphoma and chronic lymphocytic leukemia (CLL) and is an active investigator in several clinical trials. Her research is centered on B cell lymphomas and CLL. Dr. Mulvey is focused on the study and manipulation of the interaction between the body’s own immune system and cancerous cells. She also has a special interest in health realted quality of life and the use of patient reported outcomes in clinical trials, and has received honors from the Lymphoma Research Foundation (LRF) and the NIH.

Javier Pinilla-Ibarz, MD, PhD, is physician scientist Senior Member, Head of Lymphoma Section and Director of Immunotherapy in the Malignant Hematology Department at H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida.

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006, and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. Dr. Pinilla-Ibarz has participated in multiple clinical trials involving several kinase inhibitors, many of them now FDA approved.
He has been involved in developing new immunotherapeutic approaches in malignant hematology with special emphasis of restoring the impaired immune response of patients with chronic leukemias. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. He has been involved in the development of a Wilms tumor 1 vaccine for leukemias and other solid tumor now in phase III trial across the world. His laboratory is interested in epigenetic immunoregulation in lymphoid malignancies such as B and T cell lymphomas through the use of epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other research focuses are on the interaction of kinase inhibitors with the immune system and how to use these drugs to improve current immune therapeutics approaches.

Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center.

After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College.
Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous co-stimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bi-specific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells).

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

I am a Professor of Medicine and Clinical Director of the UAMS Myeloma Center located on the campus of the University of Arkansas for Medical Sciences. I earned my medical degree from Erasmus University, Rotterdam, Netherlands, and my Ph.D. at the Imperial College of Science, Medicine and Technology, University of London. I trained in Internal Medicine and Hematology in the United Kingdom, in Bone Marrow Transplantation at John Radcliffe University Hospital in Oxford and attended the Royal Postgraduate Medical School in London. Subsequently, I was a Fogarty Fellow at the National Institutes of Health.I hold the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee is an international expert on Castleman Disease, with one of the largest populations of Castleman Disease patients in the world. I am the co-founder of the Castleman Disease Collaborative Network (CDCN) and presently serve as the co-chair of the Scientific Advisory Committee of the CDCN. I was the principal investigator for all siltuximab studies including the phase II randomized trial leading to the worldwide approval of siltuximab for iMCD. I have published more than 50 scientific papers on Castleman Disease including the publication in the journal, Blood, which formulated the International, evidence-based consensus treatment guidelines for iMCD

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

Dr. Barr is a Professor of Medicine at the University of Rochester and serves as Assistant Director for Clinical Research at the Wilmot Cancer Institute and Medical Director of the Wilmot Clinical Trials Office. Since his appointment as Medical Director in 2013, he has overseen substantial growth and specialization of the Clinical Trials Office, contributing to a doubling of clinical trial accrual.
Dr. Barr completed fellowship training in Hematology and Oncology at Case Western Reserve University, where he was also an NIH/NCI K12 Paul Calabresi Scholar. Clinical trials expertise was further developed through the American Society of Hematology Clinical Research Training Institute. He has since led single-institution, multi-center, and cooperative group studies evaluating novel agents for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.
His research focuses on the clinical development of novel therapeutic combinations incorporating inhibitors targeting the B-cell receptor signaling pathway. This work has been supported by a Wilmot Fellowship, the University of Rochester NIH SPORE in Lymphoma, and a career development award from the Lymphoma Research Foundation. Dr. Barr is an active member of the SWOG Lymphoma Committee and has served as study chair for SWOG S1608 and Principal Investigator for SWOG S1108 and S0801. He also serves as the Rochester site PI for SWOG, is a member of the SWOG Board of Governors and serves as the PI for the Rochester’s Lead Academic Participating Site award from the NCI Clinical Trials Network in 2019, with renewal in 2026.

Dr. Nicole Lamanna serves as the Judy Horrigan Professor of Medicine and Director of the Chronic Lymphocytic Leukemia (CLL) Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias with a focus on chronic lymphocytic leukemia (CLL). Her clinical research focus has been the development of novel combination therapies that include immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, monoclonal antibodies as well new agents in development for this disease. She is a staunch patient advocate and participates regularly in CLL patient advocacy groups with the goal of educating patients about their disease and treatment options. She has lectured and chaired CLL sessions at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, Lancet and The New England Journal of Medicine.

I am a Professor of Medicine and Clinical Director of the UAMS Myeloma Center located on the campus of the University of Arkansas for Medical Sciences. I earned my medical degree from Erasmus University, Rotterdam, Netherlands, and my Ph.D. at the Imperial College of Science, Medicine and Technology, University of London. I trained in Internal Medicine and Hematology in the United Kingdom, in Bone Marrow Transplantation at John Radcliffe University Hospital in Oxford and attended the Royal Postgraduate Medical School in London. Subsequently, I was a Fogarty Fellow at the National Institutes of Health.I hold the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee is an international expert on Castleman Disease, with one of the largest populations of Castleman Disease patients in the world. I am the co-founder of the Castleman Disease Collaborative Network (CDCN) and presently serve as the co-chair of the Scientific Advisory Committee of the CDCN. I was the principal investigator for all siltuximab studies including the phase II randomized trial leading to the worldwide approval of siltuximab for iMCD. I have published more than 50 scientific papers on Castleman Disease including the publication in the journal, Blood, which formulated the International, evidence-based consensus treatment guidelines for iMCD

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.